Vulvovaginal atrophy (VA) refers to a constellation of physiologic changes in the skin and mucous membranes of the vulva and vagina in response to hypoestrogenic state, most often caused by menopause. Several professional societies suggest that this condition can be referred to as the genitourinary syndrome of menopause (GSM). Vulvovaginal atrophy is also known as vaginal atrophy, urogenital atrophy, and atrophic vaginitis.
After completing this course, you should be able to:
1. Identify women at high risk of symptomatic vulvovaginal atrophy, especially subsets who experience early menopause or have induced menopause from surgery, radiation therapy (RT), or a therapeutic or chemotherapeutic intervention.
2. Recognize the spectrum of symptoms related to vulvovaginal atrophy and its medical implications, such as recurrent urinary tract infections, in both sexually active and non-sexually active women.
3. Diagnose vulvovaginal atrophy based on physical exam findings and appropriate clinical evaluations.
4. Describe diverse treatment modalities and their mode of application, risks, benefits, and side effects.
5. Recommend treatment for each woman with symptomatic vulvovaginal atrophy, based on her needs, medical history, and personal preferences.
1. Epidemiology
2. Pathophysiology
3. Diagnosis
4. Treatment
5. Special Populations
6. Future Management
This course is intended for doctors.